CoChat
Sign Up
Cited by 4,000

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Microtubules as a target for anticancer drugs

Jordan, Mary Ann, Wilson, Leslie·2004·Nature Reviews Cancer
DOI 10.1038/nrc1317
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc1317

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 165

  1. Luduena, R. F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytology 178, 207–275 (1998). Comprehensive review of tubulin isotypes and post-translational modifications. · DOI
  2. Verdier-Pinard, P. et al. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 42, 12019–12027 (2003). Describes analysis of tubulin isotypes, mutations and post-translational modifications by liquid chromatography/electrospray-ionization mass spectrometry in paclitaxel-sensitive and -resistant cell lines. · DOI
  3. Ligon, L. A., Shelly, S. S., Tokito, M. & Holzbaur, E. L. The microtubule plus-end proteins EB1 and dynactin have differential effects on microtubule polymerization. Mol. Biol. Cell 14, 1405–1417 (2003). · DOI
  4. Galmarini, C. M. et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer 88, 1793–1799 (2003). · DOI
  5. Giodini, A. et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62, 2462–2467 (2002).
  6. Cassimeris, L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr. Opin. Cell Biol. 14, 18–24 (2002). · DOI
  7. Spittle, C., Charrasse, S., Larroque, C. & Cassimeris, L. The interaction of TOGp with microtubules and tubulin. J. Biol. Chem. 275, 20748–20753 (2000). · DOI
  8. Maney, T., Wagenbach, M. & Wordeman, L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J. Biol. Chem. 276, 34753–34758 (2001). · DOI
  9. Jordan, M. A. & Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123–130 (1998). · DOI
  10. Giannakakou, P., Sackett, D. & Fojo, T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J. Natl Cancer Inst. 92, 182–183 (2000). · DOI
  11. Gerzon, K. in Anticancer Agents Based on Natural Product Models (eds Cassady, J. M. & Douros, J. D.) 271–317 (Academic, New York, 1980).
  12. Wordeman, L. & Mitchison, T. J. in Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 287–302 (Wiley–Liss, New York, 1994).
  13. Wilson, L. & Jordan, M. A. in Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 59–84 (Wiley–Liss, New York, 1994).
  14. McIntosh, J. R. in Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 413–434 (Wiley–Liss, New York, 1994).
  15. Waterman-Storer, C. & Salmon, E. D. Microtubule dynamics: treadmilling comes around again. Curr. Biol. 7, 369–372 (1997). · DOI
  16. Margolis, R. L. & Wilson, L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 13, 1–8 (1978). · DOI
  17. Margolis, R. L. & Wilson, L. Microtubule treadmilling: what goes around comes around. Bioessays 20, 830–836 (1998). · DOI
  18. Rodionov, V. I. & Borisy, G. G. Microtubule treadmilling in vivo. Science 275, 215–218 (1997). · DOI
  19. Shaw, S. L., Kamyar, R. & Ehrhardt, D. W. Sustained microtubule treadmilling in Arabidopsis cortical arrays. Science 300, 1715–1718 (2003). · DOI
  20. Panda, D., Miller, H. P. & Wilson, L. Rapid treadmilling of MAP-free brain microtubules in vitro and its suppression by tau. Proc. Natl Acad. Sci. USA 96, 12459–12464 (1999). · DOI
  21. Chen, W. & Zhang, D. Kinetochore fibre dynamics outside the context of the spindle during anaphase. Nature Cell Biol. 6, 227–231 (2004). Demonstration of importance of treadmilling in anaphase-chromosome poleward movement and the independence of treadmilling from the spindle matrix. · DOI
  22. Wilson, L., Panda, D. & Jordan, M. A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct. 24, 329–335 (1999). · DOI
  23. Nogales, E. Structural insights into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 30, 397–420 (2001). · DOI
  24. Wilson, L. & Jordan, M. A. Microtubule dynamics: taking aim at a moving target. Chem. Biol. 2, 569–573 (1995). · DOI
  25. Lodish, H. et al. Molecular Cell Biology (W. H. Freeman, New York, 1999).
  26. Panda, D., Miller, H. & Wilson, L. Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics. Biochemistry 41, 1609–1617 (2002). · DOI
  27. Caplow, M. & Fee, L. Concerning the chemical nature of tubulin subunits that cap and stabilize microtubules. Biochemistry 42, 2122–2126 (2003). · DOI
  28. Panda, D., Miller, H. P. & Wilson, L. Rapid treadmilling of brain microtubules free of microtubule-associated proteins in vitro and its suppression by tau. Proc. Natl Acad. Sci. USA 96, 12459–12464 (1999). · DOI
  29. Wittmann, T., Bokoch, G. & Waterman-Storer, C. Regulation of leading edge microtubule and actin dynamics downstream of Rac1. J. Cell Biol. 161, 845–851 (2003). · DOI
  30. Alli, E., Bash-Babula, J., Yang, J. -M. & Hait, W. N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 62, 6864–6869 (2002).
  31. McNally, F. Microtubule dynamics: new surprises from an old MAP. Curr. Biol. 13, 597–599 (2003). · DOI
  32. Ohi, R., Coughlin, M. L., Lane, W. S. & Mitchison, T. J. An inner centromere protein that stimulates the microtubule depolymerizing activity of a KinI kinesin. Dev. Cell 5, 309–321 (2003). · DOI
  33. Carvalho, P., Tirnauer, J. & Pellman, D. Surfing on microtubule ends. Trends Cell Biol. 13, 229–237 (2003). · DOI
  34. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel–Lindau tumour suppressor protein pVHL. Nature Cell Biol. 5, 64–70 (2003). · DOI
  35. Komarova, Y., Akhmanova, A., Kojima, S., Galjart, N. & Borisy, G. Cytoplasmic linker proteins promote microtubule rescue in vivo. J. Cell Biol. 159, 589–599 (2002). · DOI
  36. Mitchison, T. J. Microtubule dynamics and kinetochore function in mitosis. Annu. Rev. Cell Biol. 4, 527–549 (1988). · DOI
  37. Saxton, W. M. et al. Tubulin dynamics in cultured mammalian cells. J. Cell Biol. 99, 2175–2186 (1984). · DOI
  38. Rusan, N. M., Fagerstrom, C. J., Yvon, A. -M. C. & Wadsworth, P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein–α tubulin. Mol. Biol. Cell 12, 971–980 (2001). · DOI
  39. Pepperkok, R., Bre, M. H., Davoust, J. & Kreis, T. E. Microtubules are stabilized in confluent epithelial cells but not in fibroblasts. J. Cell Biol. 111, 3003–3012 (1990). · DOI
  40. Zhai, Y., Kronebusch, P. J., Simon, P. M. & Borisy, G. G. Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J. Cell Biol. 135, 201–214 (1996). · DOI
  41. Hayden, J. J., Bowser, S. S. & Rieder, C. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt cells. J. Cell Biol. 111, 1039–1045 (1990). Classic demonstration of the role of microtubule dynamic instability in the attachment of chromosomes to the mitotic spindle. · DOI
  42. Jordan, M. A. et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816–825 (1996). Demonstration that mitotic block by low concentrations of paclitaxel leads to apoptosis.
  43. Rieder, C., Schultz, A., Cole, R. & Sluder, G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J. Cell Biol. 127, 1301–1310 (1994). · DOI
  44. Shelby, R. D., Hahn, K. M. & Sullivan, K. F. Dynamic elastic behavior of α-satellite DNA domains visualized in situ in living human cells. J. Cell Biol. 135, 545–557 (1996). · DOI
  45. Mitchison, T. J. Poleward microtubule flux in the mitotic spindle; evidence from photoactivation of fluorescence. J. Cell Biol. 109, 637–652 (1989). · DOI
  46. Wilson, P. J. & Forer, A. Effects of nanomolar taxol on crane-fly spermatocyte spindles indicate that acetylation of kinetochore microtubules can be used as a marker of poleward tubulin flux. Cell Motil. Cytoskeleton 37, 20–32 (1997). · DOI
  47. Li, X. & Nicklas, R. B. Mitotic forces control a cell-cycle checkpoint. Nature 373, 630–632 (1995). · DOI
  48. Nicklas, R. B., Ward, S. C. & Gorbsky, G. J. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J. Cell Biol. 130, 929–939 (1995). · DOI
  49. Gorbsky, G. J. Cell cycle checkpoints: arresting progress in mitosis. BioEssays 19, 193–197 (1997). · DOI
  50. Zhou, J. et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol. 63, 799–807 (2003). · DOI
  51. Hamel, E. & Covell, D. G. Antimitotic peptides and depsipeptides. Curr. Med. Chem. Anti-Canc. Agents 2, 19–53 (2002). · DOI
  52. Hoffman, J. C. & Vaughn, K. C. Mitotic disrupter herbicides act by a single mechanism but vary in efficacy. Protoplasma 179, 16–25 (1994). · DOI
  53. Lacey, E. & Gill, J. H. Biochemistry of benzimidazole resistance. Acta Trop. 56, 245–262 (1994). · DOI
  54. Lobert, S., Ingram, J. & Correia, J. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Cancer Res. 59, 4816–4822 (1999).
  55. Cann, J. R. & Hinman, N. D. Interaction of chlorpromazine with brain microtubule subunit protein. Molec. Pharmacol. 11, 256–267 (1975).
  56. Boder, G. B., Paul, D. C. & Williams, D. C. Chlorpromazine inhibits mitosis of mammalian cells. Eur. J. Cell Biol. 31, 349–353 (1983).
  57. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti-Canc. Agents 2, 1–17 (2002). · DOI
  58. Jimenez-Barbero, J., Amat-Guerri, F. & Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. Anti-Canc. Agents 2, 91–122 (2002). · DOI
  59. Jordan, M. A., Toso, R. J., Thrower, D. & Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl Acad. Sci. USA 90, 9552–9556 (1993). · DOI · Paper page
  60. Chen, J. -G. & Horwitz, S. B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 62, 1935–1938 (2002).
  61. Yvon, A. -M., Wadsworth, P. & Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947–949 (1999). First demonstration that suppression of microtubule dynamics in living cells by low concentrations of paclitaxel correlates with mitotic block. · DOI
  62. Jordan, M. A. & Wilson, L. in Methods in Cell Biology, in Mitosis and Meiosis Vol. 61 (ed. Rieder, C. L.) 267–295 (Academic, New York, 1998).
  63. Skibbens, R. V., Skeen, V. P. & Salmon, E. D. Directional instability of kinetochore motility during chromosome congression and segregation in mitotic newt lung cells: a push-pull mechanism. J. Cell Biol. 122, 859–875 (1993). · DOI
  64. Waters, J. C., Mitchison, T. J., Rieder, C. L. & Salmon, E. D. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol. Biol. Cell 7, 1547–1558 (1996). · DOI
  65. Noble, R. L., Beer, C. T. & Cutts, J. H. Further biological activities of vincaleukoblastine: an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol. 1, 347–348 (1958). · DOI
  66. Gidding, C. E., Kellie, S. J., Kamps, W. A. & de Graaf, S. S. Vincristine revisited. Crit. Rev. Oncol. Hematol. 29, 267–287 (1999). · DOI
  67. Quasthoff, S. & Hartung, H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249, 9–17 (2002). · DOI
  68. Sahenk, Z., Barohn, R., New, P. & Mendell, J. R. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 51, 726–729 (1994). · DOI
  69. Jordan, M. A., Thrower, D. & Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51, 2212–2222 (1991). First demonstration that antimitotic mechanism of Vinca alkaloids does not require microtubule depolymerization.
  70. Bai, R. B., Pettit, G. R. & Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites. J. Biol. Chem. 265, 17141–17149 (1990). · DOI
  71. Wilson, L., Jordan, M. A., Morse, A. & Margolis, R. L. Interaction of vinblastine with steady-state microtubules in vitro. J. Mol. Biol. 159, 125–149 (1982). · DOI
  72. Jordan, M. A. & Wilson, L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29, 2730–2739 (1990). · DOI
  73. Na, G. C. & Timasheff, S. N. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 19, 1347–1354 (1980). · DOI
  74. Na, G. C. & Timasheff, S. N. Stoichiometry of the vinblastine-induced self-association of calf brain tubulin. Biochemistry 19, 1347–1354 (1980). · DOI
  75. Lobert, S. & Correia, J. in Methods in Enzymology Vol. 323, (ed. Johnson, M.) 77–103 (Academic Press, 2000).
  76. Jordan, M. A., Margolis, R. L., Himes, R. H. & Wilson, L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol. 187, 61–73 (1986). · DOI
  77. Singer, W. D., Jordan, M. A., Wilson, L. & Himes, R. H. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol. 36, 366–370 (1989).
  78. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T. J. Am. Chem. Soc. 93, 2325–2327 (1971). · DOI
  79. Schiff, P. B., Fant, J. & Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 277, 665–667 (1979). Classic demonstration that paclitaxel enhances microtubule polymerization and stabilizes microtubules. · DOI · Paper page
  80. Horwitz, S. B. How to make taxol from scratch. Nature 367, 593–594 (1994). · DOI
  81. Von Hoff, D. D. The taxoids: same roots, different drugs. Semin. Oncol. 24 (4 Suppl. 13), S13-3–S13-10 (1997).
  82. Markman, M. Managing taxane toxicities. Support Care Cancer 11, 144–147 (2003). · DOI
  83. Nogales, E., Wolf, S. G., Khan, I. A., Luduena, R. F. & Downing, K. A. Structure of tubulin at 6.5Å and location of the taxol-binding site. Nature 375, 424–427 (1995). First high-resolution determination of the structure of polymerized tubulin and the paclitaxel-binding site. · DOI
  84. Derry, W. B., Wilson, L. & Jordan, M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34, 2203–2211 (1995). Mechanistic analysis of suppression of microtubule dynamics by paclitaxel. · DOI
  85. Kelling, J., Sullivan, K., Wilson, L. & Jordan, M. A. Suppression of centromere dynamics by taxol in living osteosarcoma cells. Cancer Res. 63, 2794–2801 (2003).
  86. Pryor, D. E. et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41, 9109–9115 (2002). · DOI
  87. Hastie, S. B. Interactions of colchicine with tubulin. Pharmacol. Ther. 512, 377–401 (1991). · DOI
  88. Skoufias, D. & Wilson, L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin–colchicine complexes. Biochemistry 31, 738–746 (1992). · DOI
  89. Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21–38 (2002). Review of mechanism of action of combretastatins and their therapeutic potential. · DOI
  90. Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002). · DOI
  91. Tozer, G. M. et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413–6422 (2001).
  92. Prise, V. E., Honess, D. J., Stratford, M. R., Wilson, J. & Tozer, G. M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717–726 (2002).
  93. Davis, P. D. et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62, 7247–7253 (2002).
  94. Dumontet, C. & Sikic, B. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061–1070 (1999). · DOI
  95. Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. & Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468–7485 (2003). · DOI
  96. Safa, A. R. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr. Med. Chem. Anti-Canc. Agents 4, 1–17 (2004). · DOI
  97. Thomas, H. & Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159–165 (2003). · DOI · Paper page
  98. Geney, R., Ungureanu, M., Li, D. & Ojima, I. Overcoming multidrug resistance in taxane chemotherapy. Clin. Chem. Lab. Med. 40, 918–925 (2002). · DOI
  99. Kavallaris, M. et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61, 5803–5809 (2001).
  100. Minotti, A. M., Barlow, S. B. & Cabral, F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlated with changes in the level of polymerized tubulin. J. Biol. Chem. 266, 3987–3994 (1991). · DOI
  101. James, S. W., Silflow, C. D., Stroom, P. & Lefebvre, P. A. A mutation in the α1-tubulin gene of Chlamydomonas reinhardtii confers resistance to anti-microtubule herbicides. J. Cell Sci. 106, 209–218 (1993). · DOI
  102. Lee, W. -P. Purification and characterization of tubulin from parental and vincristine-resistant HOB1 lymphoma cells. Arch. Biochem. Biophys. 319, 498–503 (1995). · DOI
  103. Ohta, S. et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. 85, 290–297 (1994). · DOI
  104. Laing, N. M. et al. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58, 1332–1337 (1998).
  105. Burkhart, C. A., Kavallaris, M. & Band Horwitz, S. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta. 1471, O1–O9 (2001).
  106. Dumontet, C. et al. Resistance to microtubule–targeted cytotoxins in a K562 leukemia cell variant is associated with altered tubulin expression. Elec. J. Oncol. 2, 33–44 (1999).
  107. Giannakakou, P. et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl Acad. Sci. USA 97, 2904–2909 (2000). · DOI
  108. Goncalves, A. et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl Acad. Sci. USA 98, 11737–11741 (2001). First demonstration of sensitivity of mitotic progression to precise regulation of microtubule dynamics and of the association of increased microtubule dynamics with paclitaxel resistance. · DOI
  109. Haber, M. et al. Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. 270, 31269–31275 (1995). · DOI
  110. Jaffrezou, J. -P. et al. Novel mechanism of resistance to paclitaxel in human K562 leukemia cells by combined selection with PSC833. Oncology Res. 7, 517–527 (1995).
  111. Kavallaris, M. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest. 100, 1–12 (1997). · DOI
  112. Poruchynsky, M. S. et al. Accompanying protein alterations in malignant cells with a microtubule- polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. 62, 1469–1480 (2001). · DOI
  113. Ranganathan, S. et al. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56, 2584–2589 (1996).
  114. Verdier-Pinard, P. et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42, 5349–5357 (2003). · DOI
  115. Kavallaris, M., Burkhardt, C. A. & Horwitz, S. B. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 80, 1020–1025 (1999). · DOI
  116. Martello, L. A. et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 6, 1978–1987 (2000).
  117. Martello, L. A. et al. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res. 63, 1207–1213 (2003).
  118. Wendell, K. L., Wilson, L. & Jordan, M. A. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochore-microtubule attachment and in centrosomes. J. Cell Sci. 104, 261–274 (1993). · DOI
  119. Panda, D., Miller, H., Islam, K. & Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl Acad. Sci. USA 94, 10560–10564 (1997). · DOI
  120. Seidman, A., Scher, H. I., Petrylak, D., Derrshaw, D. D. & Curley, T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 147, 931–934 (1992). · DOI
  121. Hudes, G. R. et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 10, 1754–1761 (1992). · DOI
  122. Hudes, G. R. et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 22, 41–45 (1995).
  123. Knick, V. C., Eberwein, D. & Miller, C. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl Cancer Inst. 87, 1072–1077 (1995). · DOI
  124. Photiou, A., Shah, P., Leong, L., Moss, J. & Retsas, S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur. J. Cancer 33, 463–470 (1997). · DOI
  125. Dieras, V. et al. Docetaxel in combination with doxorubicin or vinorelbine. Eur. J. Cancer 33 (Suppl 7), 20–22 (1997). · DOI
  126. Garcia, P., Braguer, D., Carles, G. & Briand, C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anticancer Drugs 6, 533–544 (1995). · DOI
  127. Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M. & Fojo, T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer 75, 57–63 (1998). · DOI
  128. Duflos, A., Kruczynski, A. & Barret, J. -M. Novel aspects of natural and modified Vinca alkaloids. Curr. Med. Chem. Anti-Canc. Agents 2, 55–70 (2002). · DOI
  129. Plosker, G. L. & Figgitt, D. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63, 803–843 (2003). · DOI
  130. Sandler, A. B. Chemotherapy for small cell lung cancer. Semin. Oncol. 30, 9–25 (2003). · DOI
  131. Armitage, J. O. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas. Clin. Lymphoma 3, S5–S11 (2002). · DOI
  132. Jassem, J. et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. 14, 1634–1639 (2003). · DOI
  133. Rossi, A. et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res. 23, 1657–1664 (2003).
  134. Seidman, A. D. Monotherapy options in the management of metastatic breast cancer. Semin. Oncol. 30, 6–10 (2003). · DOI
  135. Okouneva, T., Hill, B. T., Wilson, L. & Jordan, M. A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther. 2, 427–436 (2003).
  136. Panda, D. et al. Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 39, 14121–14127 (2000). · DOI
  137. Kerksiek, K., Mejillano, M. R., Schwartz, R. E., Georg, G. I. & Himes, R. H. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett. 377, 59–61 (1995). · DOI
  138. Bai, R. B. et al. Halichondrin B and homohalichondrin B, marine natural products binding in the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882–15889 (1991). · DOI
  139. Luduena, R. F., Roach, M. C., Prasad, V. & Pettit, G. R. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem. Pharmacol. 45, 421–427 (1993). · DOI
  140. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Cancer Res. 61, 1013–1021 (2001).
  141. Hamel, E. Natural products which interact with tubulin in the Vinca domain: maytansine, rhizoxin, phomopsin A, Dolastatins 10 and 15 and halichondrin B. Pharmacol. Ther. 55, 31–51 (1992). · DOI
  142. Bai, R., Durso, N. A., Sackett, D. L. & Hamel, E. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38, 14302–14310 (1999). · DOI
  143. Loganzo, F. et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63, 1838–1845 (2003).
  144. Hamel, E. et al. Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem. Pharmacol. 51, 53–59 (1996). · DOI
  145. Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363–375 (2003). · DOI · Paper page
  146. Lakhani, N. J., Sarkar, M. A., Venitz, J. & Figg, W. D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23, 165–172 (2003). · DOI
  147. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N. & Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 57, 3208–3213 (1997).
  148. Manfredi, J. J., Parness, J. & Horwitz, S. B. Taxol binds to cell microtubules. J. Cell Biol. 94, 688–696 (1982). · DOI
  149. Parness, J. & Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91, 479–487 (1981). · DOI
  150. Diaz, J. F. & Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32, 2747–2755 (1993). · DOI
  151. Belani, C. P., Langer, C. TAX 326 Study Group. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38 (Suppl. 4), 13–19 (2002). · DOI
  152. Fossella, F. V., Lynch, T. & Shepherd, F. A. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38, 5–12 (2002). · DOI
  153. Bollag, D. M. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325–2333 (1995).
  154. Wartmann, M. & Altmann, K. H. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anti-Canc. Agents 2, 123–148 (2002). · DOI
  155. Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to apclitaxel but possessing superior sntiumor efficacy. Clin. Cancer Res. 7, 1429–1437 (2001).
  156. Kamath, K. & Jordan, M. A. Suppression of microtubule dynamics by epothilone B in living MCF7 cells. Cancer Res. 63, 6026–6031 (2003).
  157. ter Haar, E. et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243–250 (1996). · DOI · Paper page
  158. Honore, S. et al. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol. Cancer Ther. 2, 1303–1311 (2003).
  159. Hung, D. T., Chen, J. & Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. 3, 287–293 (1996). · DOI · Paper page
  160. Kavallaris, M., Verrills, N. M. & Hill, B. T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Update 4, 392–401 (2001). · DOI
  161. Kowalski, R. J. et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52, 613–622 (1997). · DOI
  162. Smaletz, O. et al. Pilot study of epothilone B analog (BMS–247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann. Oncol. 14, 1518–1524 (2003). · DOI
  163. Kelly, W. et al. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin. Cancer Res. 9, 2098–2107 (2003).
  164. Hudes, G. et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J. Clin. Oncol. 20, 1115–1127 (2002). · DOI
  165. Dahllof, B., Billstron, A., Cabral, F. & Hartley-Asp, B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53, 4573–4581 (1993).

Cited by

Sorted by citations

See all 4,000

Metadata

Authors
Jordan, M. A., & Wilson, L.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2004-04
Volume
4
Issue
4
Pages
253-265
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc1317
Cited by
4,000
References
2
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review